What is Neoproteomics?
Founded in 2006 and headquartered in Moreland Hills, Ohio, NeoProteomics operates as a key contract research organization (CRO) providing advanced structural biology services. The company leverages techniques such as structural mass spectrometry and hydroxyl radical protein footprinting to support pharmaceutical and biotech clients in their drug discovery and development pipelines. NeoProteomics' offerings are critical for understanding protein-based pharmaceuticals, mapping drug interactions, identifying epitopes, and delivering integrated structural biological insights, all aimed at accelerating discovery affordably and efficiently on a global scale.
How much funding has Neoproteomics raised?
Neoproteomics has raised a total of $28K across 1 funding round:
Debt
$28K
Debt (2021): $28K with participation from PPP
Key Investors in Neoproteomics
PPP
Public-Private Partnership
What's next for Neoproteomics?
With the recent infusion of substantial expansion capital, Neoproteomics is strategically positioned for accelerated growth. This financing is expected to bolster its capabilities in contract research, potentially expanding its service offerings in protein drug interaction mapping and epitope mapping. The company's focus on serving the pharmaceutical and biotech industries suggests that future investments will likely target enhancing its technological infrastructure and broadening its client base, further solidifying its role in the drug discovery ecosystem.
See full Neoproteomics company page
